Dynamic Technology Lab Private Ltd Invests $397,000 in Repligen Co. (NASDAQ:RGEN)

Dynamic Technology Lab Private Ltd bought a new stake in Repligen Co. (NASDAQ:RGEN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 2,760 shares of the biotechnology company's stock, valued at approximately $397,000.

Other hedge funds also recently made changes to their positions in the company. UMB Bank n.a. lifted its position in Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after buying an additional 110 shares during the period. Oppenheimer & Co. Inc. bought a new position in shares of Repligen in the 4th quarter worth about $216,000. Van ECK Associates Corp lifted its position in Repligen by 7.8% during the 4th quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company's stock valued at $6,078,000 after acquiring an additional 3,066 shares during the period. Stephens Investment Management Group LLC boosted its stake in Repligen by 7.4% during the fourth quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company's stock worth $77,267,000 after acquiring an additional 37,057 shares in the last quarter. Finally, Sanctuary Advisors LLC purchased a new stake in Repligen in the third quarter worth about $233,000. 97.64% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Margaret Pax bought 250 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were bought at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the transaction, the director now owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.20% of the company's stock.

Repligen Stock Performance

Shares of RGEN stock traded down $0.00 on Tuesday, reaching $127.26. The stock had a trading volume of 304,749 shares, compared to its average volume of 700,168. The stock has a market cap of $7.15 billion, a P/E ratio of -249.81, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen Co. has a 1 year low of $102.97 and a 1 year high of $182.52. The company has a 50 day simple moving average of $142.43 and a 200 day simple moving average of $146.19.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. Equities research analysts expect that Repligen Co. will post 1.72 EPS for the current year.

Analyst Ratings Changes

Several analysts recently weighed in on RGEN shares. Canaccord Genuity Group upped their price target on Repligen from $165.00 to $170.00 and gave the stock a "hold" rating in a research note on Friday, February 21st. TD Cowen initiated coverage on Repligen in a research note on Monday, February 10th. They issued a "buy" rating and a $200.00 target price on the stock. Canaccord Genuity Group began coverage on Repligen in a research report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price target for the company. JPMorgan Chase & Co. upped their price target on shares of Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Finally, StockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a research note on Friday, April 4th. Seven equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $178.64.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.